Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 荣昌生物
Other Market Stock Code688331
H-Share Offer PriceHK$ 52.10
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameRemegen
Stock Code09995
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家正在進入商業化階段的生物製藥公司,致力於發現、開發和商業化創新的、有特色的生物藥,用於治療中國乃至全球多種醫療需求未被滿足的自身免疫、腫瘤科和眼科疾病。
Listing Date2020-11-09
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國山東省自由貿易試驗區煙台片區煙台開發區北京中路58號
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.remegen.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 52.10 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 26,050
Par ValueRMB 1.0 / shares
Offer Period2020-10-28 to 2020-11-02
Global Offering Shares76,537,000 shares
HK Public Offer Shares (Initial)7,654,000 shares (10.0%)
Public Offer Lots (Initial)15,308lots (Pool A7,654lots,Pool B7,654lots)
International Placing Shares (Initial)68,883,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO478,356,202 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share44.2%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 3,987,577,700

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 26,050
2 lots 1,000 HK$ 52,100
3 lots 1,500 HK$ 78,150
4 lots 2,000 HK$ 104,200
5 lots 2,500 HK$ 130,250
6 lots 3,000 HK$ 156,300
7 lots 3,500 HK$ 182,350
8 lots 4,000 HK$ 208,400
9 lots 4,500 HK$ 234,450
10 lots 5,000 HK$ 260,500
12 lots 6,000 HK$ 312,600
14 lots 7,000 HK$ 364,700
16 lots 8,000 HK$ 416,800
18 lots 9,000 HK$ 468,900
20 lots 10,000 HK$ 521,000
30 lots 15,000 HK$ 781,500
40 lots 20,000 HK$ 1,042,000
50 lots 25,000 HK$ 1,302,500
60 lots 30,000 HK$ 1,563,000
70 lots 35,000 HK$ 1,823,500
80 lots 40,000 HK$ 2,084,000
90 lots 45,000 HK$ 2,344,500
100 lots 50,000 HK$ 2,605,000
120 lots 60,000 HK$ 3,126,000
140 lots 70,000 HK$ 3,647,000
160 lots 80,000 HK$ 4,168,000
180 lots 90,000 HK$ 4,689,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
200 lots 100,000 HK$ 5,210,000
400 lots 200,000 HK$ 10,420,000
600 lots 300,000 HK$ 15,630,000
800 lots 400,000 HK$ 20,840,000
1,000 lots 500,000 HK$ 26,050,000
1,200 lots 600,000 HK$ 31,260,000
1,400 lots 700,000 HK$ 36,470,000
1,600 lots 800,000 HK$ 41,680,000
1,800 lots 900,000 HK$ 46,890,000
2,000 lots 1,000,000 HK$ 52,100,000
2,500 lots 1,250,000 HK$ 65,125,000
3,000 lots 1,500,000 HK$ 78,150,000
3,500 lots 1,750,000 HK$ 91,175,000
4,000 lots 2,000,000 HK$ 104,200,000
4,500 lots 2,250,000 HK$ 117,225,000
5,500 lots 2,750,000 HK$ 143,275,000
6,000 lots 3,000,000 HK$ 156,300,000
6,500 lots 3,250,000 HK$ 169,325,000
7,654 lots 3,827,000 HK$ 199,386,700

Stock Connect Inclusion Analysis

HK Market Cap HK$ 16.73B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 24,922,358,124
H-Share Market Cap (at Offer Price)HK$ 5,567,842,441
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣430.3百萬元
Period-End Cash Balance人民幣34.5百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 11,3210
Cost of sales -8,9320
Gross profit 2,3890
Other income and gains, net 15,37738,481
Selling and distribution expenses 0-621
Administrative expenses -29,125-68,434
Operating profit -229,893-386,491
Net finance costs -40,055-43,789
Profit before tax -269,948-430,280
Income tax expense 00
Profit for the year -269,948-430,280
Profit attributable to owners -269,948-430,280
Balance Sheet
Item 201820192020-06
Cash and cash equivalents 5,06934,545
Trade and bills receivables 10,9691,058
Inventories 29,67131,247
Total current assets 64,884137,574
Total assets 531,092689,311
Total current liabilities 996,939856,953
Total liabilities 1,029,270921,280
Total equity -498,178-231,969
Equity attributable to owners -498,178-231,969
Interest-bearing borrowings 060,0000
Cash Flow Statement
Item 20182019-0620192020-06
Net cash from operating activities -128,028-282,746
Net cash from investing activities -77,172-95,100
Depreciation of PP&E 20,54218,92040,20323,458
Depreciation of right-of-use assets 8038151,7696,766
Amortisation of intangible assets 1,294400800400
Purchase of PP&E -83,722-38,261-65,209-181,436
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 69.8
First Day OpenHK$ 60.6
First Day Change33.97%
First Day Volume35719000.0
First Day Turnover2297640000.0
Use of Proceeds
1、約50.0%,或243.65百萬美元(1,888.29百萬港元),將主要用于候選藥物的臨床開發及商業化; 2、約25.0%,或121.82百萬美元(944.14百萬港元)將用于撥付建設新生產設施以擴大商業生產產能; 3、約15.0%,或73.09百萬美元(566.49百萬港元)將用于償還榮昌制藥借款; 4、約10.0%,或48.73百萬美元(377.66百萬港元)將用作一般企業及營運資金用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 UBS Securities Hong Kong Limited CE BIN466 中银国际亚洲有限公司 CE AET863 交银国际证券有限公司 CE APJ121 海通国际证券有限公司 CE AAF806 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 UBS Securities Hong Kong Limited CE BIN466 中银国际亚洲有限公司 CE AET863 交银国际证券有限公司 CE APJ121 海通国际证券有限公司 CE AAF806 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 BlackRock Funds 154,997,500 HKD — 3.89% — 6 months 2021-05-09
2 Cherry Tomatoes International Limited 38,736,350 HKD — 0.97% — 6 months 2021-05-09
3 Cormorant Asset Management, LP 77,498,750 HKD — 1.94% — 6 months 2021-05-09
4 CPE Greater China Enterprises Growth Fund 46,499,250 HKD — 1.17% — 6 months 2021-05-09
5 Fidelity International 294,495,250 HKD — 7.39% — 6 months 2021-05-09
6 GIC Private Limited 77,498,750 HKD — 1.94% — 6 months 2021-05-09
7 Hillhouse Funds 77,498,750 HKD — 1.94% — 6 months 2021-05-09
8 Hudson Bay Master Fund LTD 77,498,750 HKD — 1.94% — 6 months 2021-05-09
9 Janchor Partners Pan-Asian Master Fund 92,998,500 HKD — 2.33% — 6 months 2021-05-09
10 Lake Bleu Prime Healthcare Master Fund Limited 154,997,500 HKD — 3.89% — 6 months 2021-05-09
11 LAV Amber Limited 154,997,500 HKD — 3.89% — 6 months 2021-05-09
12 Matthews Asia Funds 77,498,750 HKD — 1.94% — 6 months 2021-05-09
13 Octagon Investments Master Fund LP 61,999,000 HKD — 1.55% — 6 months 2021-05-09
14 OrbiMed Funds 116,235,100 HKD — 2.92% — 6 months 2021-05-09
15 Vivo Funds 77,498,750 HKD — 1.94% — 6 months 2021-05-09
16 加皇环球资产管理(亚洲)有限公司 54,236,100 HKD — 1.36% — 6 months 2021-05-09
17 新华资本管理有限公司 38,736,350 HKD — 0.97% — 6 months 2021-05-09
18 易方达基金管理有限公司 42,617,800 HKD — 1.07% — 6 months 2021-05-09
19 中国生物制药有限公司 46,499,250 HKD — 1.17% — 6 months 2021-05-09

Directors & Management

PositionChinese nameEnglish Name
Chairman王威東—
Company Secretary李嘉、譚栢如—
No director data available.

Major Shareholders

Major Shareholders & Holdings王威東先生、房健民博士等一致行動人士為控股股東,合共持有約47.32%股份;其他主要股東包括國投創業、PAG、深創投等。
About this page

This page shows Remegen (09995) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect